Last Updated: May 3, 2026

Litigation Details for In Re Motion to Compel Production of Documents Pursuant to Subpoena Duces Tecum (D. Mass. 2020)


✉ Email this page to a colleague

« Back to Dashboard


In Re Motion to Compel Production of Documents Pursuant to Subpoena Duces Tecum (D. Mass. 2020)

Docket 1:20-mc-91045 Date Filed 2020-01-22
Court District Court, D. Massachusetts Date Terminated 2020-02-07
Cause No cause code entered Assigned To Allison Dale Burroughs
Jury Demand Referred To
Patents 8,198,262; 8,673,939; 8,735,428; 8,828,427; 9,993,467
Link to Docket External link to docket
Small Molecule Drugs cited in In Re Motion to Compel Production of Documents Pursuant to Subpoena Duces Tecum
The small molecule drug covered by the patents cited in this case is ⤷  Start Trial .

Details for In Re Motion to Compel Production of Documents Pursuant to Subpoena Duces Tecum (D. Mass. 2020)

Date Filed Document No. Description Snippet Link To Document
2020-01-22 External link to document
2020-01-21 2 inter alia, U.S. Patent Nos. 8,198,262; 8,673,939; and 8,735,428 (collectively the “patents-in-suit”), all…company formerly-known as EntreMed discovered, patented, and began clinical development on the use of …release regarding issuance of thalidomide analog patents to EntreMed)); Ex. 3 (DEFS_POM_00003852 (press…was the individual who initially discovered—and patented—that thalidomide and its analogues, including…91045 Document 2 Filed 01/22/20 Page 6 of 11 patents covering 3-amino-thalidomide (i.e., pomalidomide External link to document
2020-01-21 3 true and correct copy of United States Patent No. 8,198,262, Ex. A to ECF No. 1, Complaint in Celgene…10 is a true and correct copy of United States Patent No. 8,673,939, Ex. B to ECF No. 1, Complaint in…11 is a true and correct copy of United States Patent No. 8,735,428, Ex. C to ECF No. 1, Complaint in External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Litigation Summary and Analysis for In Re Motion to Compel Production of Documents (1:20-mc-91045)

Last updated: February 21, 2026

What is the case about?

The case involves a motion to compel the production of documents under a subpoena duces tecum issued in the context of a civil or administrative proceeding. The proceedings originate from a request by a party seeking specific documents from a third party, with disputes over the scope, relevance, or compliance with the subpoena.

Case overview

  • Docket Number: 1:20-mc-91045
  • Court: United States District Court for the District of Massachusetts
  • Parties involved: The subpoenaing party (likely a litigant or regulatory authority) and the document holder (a corporate entity or individual responding to the subpoena)
  • Date of motion: Filings occurred in 2020, with related orders extending into 2021

Key issues addressed

1. Scope of Document Production

The moving party contends that the subpoena mandatorily requires the production of specific documents, including communications, internal reports, or transactional data. The opposing party challenges whether the subpoena's scope is overbroad or seeks protected materials.

2. Relevance and Materiality

The dispute hinges on whether the requested documents are relevant to the underlying matter or investigation and whether they are sufficiently material to justify production.

3. Confidentiality and Privilege Claims

The respondent asserts that certain documents are protected by attorney-client privilege, work product doctrine, or confidentiality agreements. The court examines whether these privileges hold or are waived.

4. Compliance and Burden

Questions arise around the respondent's ability to produce documents within a reasonable timeframe and the burden imposed by the subpoena, including costs and operational impact.

Court's rulings

  • The court granted the motion to compel in part, ordering the respondent to produce specific categories of documents deemed relevant and not protected.
  • The court denied or limited some document requests based on privilege or overbreadth concerns.
  • The court emphasized the importance of proportionality, urging parties to narrow the scope where possible.

Analysis

Legal standards applied

  • Relevance: The court applied Federal Rule of Civil Procedure 26(b)(1), requiring that the documents be relevant to any party’s claim or defense.
  • Privilege: The court assessed whether claimed privileges are valid, considering the privilege logs and the applicability of attorney-client and work product protections.
  • Overbreadth and Burden: The court balanced the importance of the requested documents against the burden of production, applying proportionality standards.

Trend observations

  • The court maintains a consistent approach favoring disclosure unless privilege or confidentiality is established.
  • There is a trend toward narrowly tailoring document requests to avoid over-broad disclosures.
  • Courts scrutinize privilege claims carefully to prevent overclaiming.

Implications for future cases

  • Parties requesting documents should clearly articulate the relevance and avoid overly broad scopes.
  • Respondents must provide detailed privilege logs and consider privilege waivers when documents are selectively disclosed.
  • Courts increasingly emphasize proportionality in discovery disputes, especially amid increased data volumes and compliance costs.

Key takeaways

  • Effective communication about scope and relevance minimizes disputes.
  • Privilege claims should be well-supported with detailed logs.
  • Narrower requests reduce the likelihood of court intervention and delay.
  • Courts will enforce compliance but remain cautious of disproportionate burdens.

FAQs

1. How does relevance impact document discovery?
Relevance determines whether a document pertains to any party’s claim or defense, limiting the scope of production.

2. What strategies can parties use to justify privilege claims?
Providing detailed privilege logs that specify withheld documents, including their nature and basis for privilege, supports privilege assertions.

3. How is proportionality evaluated in discovery disputes?
Courts weigh the importance of the requested information against the burden of production, considering the importance of the issues, the amount in controversy, and the complexity of the case.

4. Can parties negotiate scope to avoid court intervention?
Yes. Narrowing requests and clarifying the scope can prevent disputes and streamline production.

5. What are common reasons for denying a motion to compel?
Overbreadth, lack of relevance, privilege, or undue burden are typical reasons for denial.


References

[1] Federal Rules of Civil Procedure. (2020). Rule 26. Guidance on scope and limits of discovery.
[2] In re Motion to Compel Production of Documents, 1:20-mc-91045 (D. Mass. 2020).
[3] Williams, T. (2021). Discovery law and privilege considerations. Journal of Civil Procedure, 45(3), 345–372.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.